The role of ezetimibe in the prevention of cardiovascular disease: Where do we stand after ARBITER 6-HALTS
Nutrition, Metabolism & Cardiovascular Diseases 06/23/2010
Howard WJ et al. – One of the important conclusions of the SANDS Trail is that ezetimibe remains an effective adjunctive medication for use in patients who do not reach their LDL–C goals on statin monotherapy. However, as a significant residual risk for ASCVD remains even after aggressive goals for LDL–C and non–HDL–C are reached, current treatment strategies should emphasize managing of all cardiac risk factors and increasing HDL in addition to the attainment and maintenance of recommended goals for LDL–C and non–HDL–C. Hence, ezetimibe should be considered as an important component of broad–spectrum management of lipid risk factors with therapy that includes statins, niacin, bile acid sequestrants, fibrates and Omega 3 fatty acids in appropriate combinations in addition to therapeutic life change.